Drug Discovery Research, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, Japan.
J Med Chem. 2011 Jan 13;54(1):387-91. doi: 10.1021/jm101031u. Epub 2010 Dec 9.
We describe the preparation and evaluation of a novel series of glycine transporter 1 (GlyT1) inhibitors derived from a high-throughput screening hit. The SAR studies resulted in the discovery of 3-biphenyl-4-yl-4-(2-fluorophenyl)-5-isopropyl-4H-1,2,4-triazole (6p). A pharmacokinetic study was also conducted and revealed that 6p had excellent oral bioavailability and ameliorated learning impairment in passive avoidance tasks in mice.
我们描述了一种新型甘氨酸转运蛋白 1(GlyT1)抑制剂系列的制备和评估,该抑制剂源于高通量筛选的命中化合物。SAR 研究发现了 3-联苯-4-基-4-(2-氟苯基)-5-异丙基-4H-1,2,4-三唑(6p)。还进行了一项药代动力学研究,结果表明 6p 具有优异的口服生物利用度,并改善了小鼠在被动回避任务中的学习障碍。